Zydus Lifesciences Ltd - Specialty Portfolio Growth to Drive Margins
Sharekhan's research report onZydus Lifesciences We reiterate a Buy on Zydus as domestic sales for February 2024 grew by 11.2% (IPM grew by 9%) and...
383 Views
Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play
The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...
211 Views
Zydus Lifesciences - Excluding One-Offs, Earnings In-Line with Estimates
Zydus Lifesciences’ 4QFY22 revenue and adjusted net profit (Rs5,250mn) for inventory provisions were in-line with our estimates.
197 Views
Miss in 3Q; US / higher RM costs drag down earnings
Cadila Healthcare (CDH) delivered lower-than-expected 3QFY22 earnings, weighed by lower Domestic Formulation (DF) / US / EM sales and increased...
243 Views
Cadila Healthcare: Indian Shines but US Slowdown Persists
It has a global presence and sells its products in the US, India, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa...
241 Views